Stockscreener 앱 받기
1.27%
전일 마감가:
$347.94
열려 있는:
$345.45
하루 거래량:
891.73K
Relative Volume:
0.33
시가총액:
$185.09B
수익:
$36.74B
순이익/손실:
$7.71B
주가수익비율:
24.13
EPS:
14.2333
순현금흐름:
$8.10B
1주 성능:
-1.57%
1개월 성능:
-7.04%
6개월 성능:
+16.80%
1년 성능:
+16.69%
1일 변동 폭
$342.84
$348.17
1주일 범위
$342.84
$357.00
52주 변동 폭
$261.43
$391.29
암젠 Stock (AMGN) Company Profile
명칭
Amgen Inc
전화
(805)447-1000
주소
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, MRK
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
343.36 | 187.56B | 36.74B | 7.71B | 8.10B | 14.23 |
LLY
Lilly Eli Co
|
928.09 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
242.00 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
206.81 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
204.15 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.68 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
암젠 Stock (AMGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | Jefferies | Hold |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-01-20 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-05 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-11-24 | 재개 | Truist | Hold |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-03 | 재개 | Raymond James | Mkt Perform |
| 2025-05-20 | 재개 | Guggenheim | Neutral |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2024-09-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2024-05-03 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 재개 | Raymond James | Mkt Perform |
| 2024-02-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 업그레이드 | Truist | Hold → Buy |
| 2023-10-20 | 재개 | JP Morgan | Neutral |
| 2023-10-17 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 재개 | BofA Securities | Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-04-24 | 재확인 | Oppenheimer | Outperform |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 재확인 | Truist | Buy |
| 2022-11-18 | 개시 | Credit Suisse | Underperform |
| 2022-10-31 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2022-10-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-09 | 재확인 | Barclays | Equal Weight |
| 2022-02-09 | 재확인 | Jefferies | Buy |
| 2022-02-09 | 재확인 | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 재확인 | Oppenheimer | Outperform |
| 2022-02-09 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-09-23 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 개시 | Daiwa Securities | Buy |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | 업그레이드 | Truist | Hold → Buy |
| 2020-10-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | 다운그레이드 | Truist | Buy → Hold |
| 2020-10-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 재개 | Guggenheim | Neutral |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-03-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-17 | 재개 | Morgan Stanley | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-05-23 | 업그레이드 | Citigroup | Neutral → Buy |
모두보기
암젠 주식(AMGN)의 최신 뉴스
Amgen (AMGN) Reveals Positive Phase 3 Results for Subcutaneous T - GuruFocus
Amgen scores with trial of on-body injected version of Tepezza in thyroid eye disease - Fierce Pharma
Amgen Inc. stock: Pipeline pivot eyes $37-38B sales amid biosimilar risks - AD HOC NEWS
Buffalo Business & Estate Services Ltd. Takes Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh Trade Ideas — BMFBOVESPA:AMGN34 - TradingView
Amgen Inc. $AMGN Position Boosted by JB Capital LLC - MarketBeat
A Look At Amgen (AMGN) Valuation After New Repatha Data And Zai Lab Oncology Collaboration - simplywall.st
Amgen Inc. (AMGN) stock price, news, quote and history - Yahoo Finance UK
Zai Lab Limited And Amgen Inc. Collaborate To Advance DLL3 Targeted Combination Therapy In Small Cell Lung Cancer - biopharmaapac.com
Thurston Springer Miller Herd & Titak Inc. Acquires 3,354 Shares of Amgen Inc. $AMGN - MarketBeat
SteelPeak Wealth LLC Has $37.88 Million Holdings in Amgen Inc. $AMGN - MarketBeat
AbbVie & Amgen: Safe Dividend Stocks for Recession Fears | 2026News and Statistics - indexbox.io
Amgen Beats Estimates by $400 Million in Q4: Here’s Why Analysts Target $350 - TIKR.com
Amgen Expands Thyroid Eye Disease Bet With New AMG 732 Rollover Study - TipRanks
Dorato Capital Management Invests $1.58 Million in Amgen Inc. $AMGN - MarketBeat
Aberdeen Group plc Acquires 27,107 Shares of Amgen Inc. $AMGN - MarketBeat
How Tavneos Safety Risks and New Oncology Pact Could Rebalance Amgen’s (AMGN) Risk‑Reward Profile - Yahoo Finance
Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance Australia
Global pharma companies that have publicly announced Trump drug pricing agreements - Reuters
2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction Territory - The Motley Fool
Amgen's Diversification Continues To Pay Off, RBC Says - Moomoo
Turning Up the Volume on IgG4-RD Awareness and Diagnosis - Amgen
Amgen Terminates Early-Stage AMG 378 Study: What Investors Should Watch Next - tipranks.com
Is Amgen Inc. (AMGN) One of the Best Pharma Stocks to Invest in Now? - Insider Monkey
Wells Fargo Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $390 - Moomoo
HF Advisory Group LLC Buys 7,548 Shares of Amgen Inc. $AMGN - MarketBeat
Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 - GlobeNewswire
Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 & 2035United Therapeutics Corporation, APEIRON Biologics, Pfizer, Bayer, and Amgen Dominate - Yahoo Finance
Trump Administration Prepares 100% Tariffs On Drugmakers Without Pricing Deals: ReportAmgen (NASDAQ:AM - Benzinga
Zai Lab (09688.HK) Enters Global Collaboration with Amgen (AMGN.US) to Explore Novel ADC and BiTE Combination Therapy - AASTOCKS.com
AMGN Stock Price, Quote & Chart | AMGEN INC (NASDAQ:AMGN) - ChartMill
Will FDA Tavneos Safety Scrutiny and New Lung Cancer Combo Trial Change Amgen's (AMGN) Narrative? - simplywall.st
AMGEN INC (AMGNCL.SN) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Amgen Inc. Stock: Biotech Leader's Strategic Pipeline and Oncology Focus Drive Long-Term Investor Va - AD HOC NEWS
Zai Lab gains after Amgen clinical trial deal (ZLAB:NASDAQ) - Seeking Alpha
Here's What You Need to Know about Amgen, Inc's AMG-145 - Yahoo
Amgen (AMGN) and Zai Lab Partner for Lung Cancer Treatment Study - gurufocus.com
Once the center of a $3.7 billion buyout, drug blamed for eight deaths draws FDA alert - The Business Journals
Zai Lab Limited and Amgen Inc Enter Global Clinical Trial Collaboration Agreement - marketscreener.com
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $432 - Moomoo
A two-drug small cell lung cancer trial pairs Amgen with Zai Lab - Stock Titan
Highline Wealth Partners LLC Sells 4,004 Shares of Amgen Inc. $AMGN - MarketBeat
Nisa Investment Advisors LLC Has $55.22 Million Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Meyer Handelman Co. - MarketBeat
Amgen Inc. $AMGN Shares Bought by Moody Lynn & Lieberson LLC - MarketBeat
Amgen Inc. (AMGN): Billionaire Ken Fisher doubles bullish position - MSN
Amgen Inc. (0R0T.IL) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Sarcopenia Treatments Market Is Going to Boom | AbbVie • Amgen • Pfizer • Novartis - openpr.com
BTC Capital Management Inc. Sells 4,196 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Given Average Rating of "Hold" by Analysts - MarketBeat
FDA Says Amgen’s Tavneos Linked to Liver Injuries, Deaths - wsj.com
암젠 (AMGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
암젠 주식 (AMGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Santos Esteban | EVP, Operations |
Feb 26 '26 |
Option Exercise |
169.19 |
54,792 |
9,270,143 |
107,119 |
| Santos Esteban | EVP, Operations |
Feb 26 '26 |
Sale |
379.12 |
54,792 |
20,772,595 |
76,618 |
0.12%
0.23%
자본화:
|
볼륨(24시간):